Effectiveness of low-dose diuretics for blood pressure reduction to optimal values in prehypertension: A randomizedclinical trial

Journal of Hypertension

Volumn 36, Issue 4, 2018, Pages 933-938

  Fuchs, Flávio D ^a   Fuchs, Sandra C ^a   Poli de Figueiredo, Carlos E ^b   Figueiredo Neto, José A ^c   Scala, Luiz César N ^d   Vilela Martin, José F ^e   Moreira, Leila B ^a   Chaves, Hilton ^f   Gomes, Marco Mota ^g   De Sousa, Marcos R ^h   E Silva, Ricardo Pereira ⁱ   Castro, Iran ^j   Cesarino, Evandro José ^k   Sousa, Ana Luiza Lima ^l   Alves, João Guilherme ^m   Steffens, André Avelino ⁿ   Brandão, Andréa Araujo ^o   Bortolotto, Luiz Aparecido ^k   Neto, Abrahão Afiune ^p   Nóbrega, Antônio C ^q   Franco, Roberto Silva ^r   Filho, Dario C Sobral ^s   Nobre, Fernando ^k   Schlatter, Rosane ^a   Gus, Miguel ^a   De David, Caroline Nespolo ^a   Rafaelli, Leticia ^a   Sesin, Guilhermo Prates ^a   Berwanger, Otávio ^u   Whelton, Paul K ^t   more..

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^d HOSPITAL UNIVERSITÁRIO JÚLIO MÜLLER   (Brazil)

^e HOSPITAL DE BASE   (Brazil)

^f FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^g Hospital do Coração   (Brazil)

^h FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

ⁱ FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^j INSTITUTO DE CARDIOLOGIA DO RIO GRANDE DO SUL   (Brazil)

^k UNIVERSITY OF SÃO PAULO   (Brazil)

^l FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^m INSTITUTO DE MEDICINA INTEGRAL PROF FERNANDO FIGUEIRA   (Brazil)

ⁿ FEDERAL UNIVERSITY OF PELOTAS   (Brazil)

^o STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^p Hospital do Coração Anis Rassi   (Brazil)

^q HOSPITAL UNIVERSITÁRIO ANTÔNIO PEDRO   (Brazil)

^r SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^s PROCAPE   (Brazil)

^t TULANE UNIVERSITY   (United States)

^u Research Institute Hoor (Hospital Do Coracao)   (Brazil)

more..

Author keywords

Chlorthalidone and amiloride; Clinical trials; Hypertension; Optimal blood pressure; Prehypertension

Indexed keywords

AMILORIDE; CHLORTALIDONE; PLACEBO; ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; BRAZIL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIURETIC THERAPY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PARALLEL DESIGN; PREHYPERTENSION; PREVENTION STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; BLOOD PRESSURE; CLINICAL TRIAL; DIASTOLE; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLE;

ADULT; AMILORIDE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CHLORTHALIDONE; DIASTOLE; DISEASE PROGRESSION; DIURETICS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREHYPERTENSION; SYSTOLE;

EID: 85049680825     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000001624     Document Type: Article

References (32)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913.
2. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and agespecific associations in 1.25 million people. Lancet 2014; 383: 1899-1911.
3. Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, et al., National High Blood Pressure Education Program Coordinating Committee. Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288:1882-1888.
4. Whelton PK, Appel LJ, Espeland MA, Applegate WB, Ettinger WH Jr, Kostis JB, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE). TONE Collaborative Research Group. JAMA 1998; 279:839-846.
5. Hypertension Prevention Collaborative Research Group. Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. The Trials of Hypertension Prevention Collaborative Research Group. Arch Intern Med 1997; 157:657-667.
6. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses, and meta-regression analyses of randomized trials. J Hypertens 2014; 32:2285-2295.
7. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31:1925-1938.
8. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
9. Qaseem A, Wilt TJ, Rich R, Humphrey LL, Frost J, Forciea MA. Clinical Guidelines Committee of the American College of Physicians and the Commission on Health of the Public and Science of the American Academy of Family Physicians. Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2017; 166:430-437.
10. Kang YY, Wang JG. The J-curve phenomenon in hypertension. Pulse (Basel) 2016; 4:49-60.
11. Sim JJ, Shi J, Kovesdy CP, Kalantar-Zadeh K, Jacobsen SJ. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol 2014; 64:588-597.
12. SPRINT Research GroupWright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 2015; 373: 2103-2116.
13. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 Years: a randomized clinical trial. JAMA 2016; 315:2673-2682.
14. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387: 957-967.
15. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive BP lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387: 435-443.
16. Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality. JAMA Cardiol 2017; 2:775-781.
17. Fuchs FD. Blood pressure-lowering drugs: essential therapy for some patients with normal BP. Expert Rev Cardiovasc Ther 2004; 2:771-775.
18. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA. Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a metaanalysis. JAMA 2011; 305:913-922.
19. Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, et al. Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol 2016; 32:569-588.
20. Gabb GM, Mangoni AA, Anderson CS, Cowley D, Dowden JS, Golledge J, et al. Guideline for the diagnosis and management of hypertension in adults - 2016. Med J Aust 2016; 205:85-89.
21. Moreira LB, Fuchs SC, Wiehe M, Gus M, Moraes RS, Fuchs FD. Incidence of hypertension in Porto Alegre, Brazil: a population-based study. J Hum Hypertens 2008; 22:48-50.
22. Kurioka S, Horie S, Inoue A, Mafune K, Tsuda Y, Otsuji Y. Risk of progression to hypertension in nonhypertensive Japanese workers aged 20-64 years. J Hypertens 2014; 32:236-244.
23. Markus MR, Stritzke J, Lieb W, Mayer B, Luchner A, Döring A, et al. Implications of persistent prehypertension for ageing-related changes in left ventricular geometry and function: the MONICA/KORA Augsburg study. J Hypertens 2008; 26:2040-2049.
24. Kanno A, Kikuya M, Ohkubo T, Hashimoto T, Satoh M, Hirose T, et al. Prehypertension as a significant predictor of chronic kidney disease in a general population: the Ohasama Study Nephrol. Dial Transplant 2012; 27:3218-3223.
25. Santos AB, Gupta DK, Bello NA, Gori M, Claggett B, Fuchs FD, et al. Prehypertension is associated with abnormalities of cardiac structure and function in the atherosclerosis risk in communities study. Am J Hypertens 2016; 29:568-574.
26. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al. Feasibility of treating prehypertension with an angiotensinreceptor blocker. N Engl J Med 2006; 354:1685-1697.
27. Lüders S, Schrader J, Berger J, Unger T, Zidek W, Böhm M, et al., PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with highnormal BP - a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008; 26:1487-1496.
28. Fuchs SC, Poli-de-Figueiredo Carlos E, Figueiredo-Neto JA, Scala LC, Whelton PK, Mosele F, et al. Effectiveness of chlorthalidone plus amiloride for the prevention of hypertension: The PREVER-prevention Randomized Clinical Trial. J Am Heart Assoc 2016; 5:e004248.
29. Fuchs FD, Fuchs SC, Moreira LB, Gus M, Nóbrega AC, Poli-de-Figueiredo CE, et al. Prevention of hypertension in patients with prehypertension: protocol for the PREVER-prevention trial. Trials 2011; 12:65.
30. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels - updated overview and meta-analyses of randomized trials. J Hypertens 2016; 34:613-622.
31. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338:b1665.
32. Cook NR, Cohen J, Hebert PR, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med 1995; 155:701-709.